Advertisement

Metastatische Tumoren des zentralen Nervensystems

  • Martin GlasEmail author
  • Björn Scheffler
  • Sied Kebir
Living reference work entry
  • 2 Downloads
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Sekundäre Hirntumoren sind Metastasen eines extrazerebralen Primärtumors, dessen Tochterzellen in der Regel hämatogen ins Gehirn gelangen. Hirnmetastasen treten bei 20–40 % aller Krebserkrankungen auf. Die häufigsten Primärtumoren sind Bronchialkarzinom, Mammakarzinom, Melanom, gastrointestinale Tumoren und Nierenzellkarzinom.

Literatur

Zitierte Literatur

  1. Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672CrossRefGoogle Scholar
  2. Aoyama H, Shirato H, Tago M et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgrey alone for treatment of brain metastases: a randomised controlled trial. J Am Med Assoc 295:2483–2491CrossRefGoogle Scholar
  3. Bachelot T, Romieu G, Campone M et al (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14:64–71CrossRefGoogle Scholar
  4. Brown PD, Pugh S, Laack NN, for the Radiation Therapy Oncology Group (RTOG) et al (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology 15:1429–1437CrossRefGoogle Scholar
  5. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, NNI L, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049–1060.  https://doi.org/10.1016/S1470-2045(17)30441-2. Epub 2017 Jul 4CrossRefPubMedPubMedCentralGoogle Scholar
  6. Davies MA, Robert C, Long GV, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Rodas IM, Vecchio MD, Lebbe C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Saiag P (2017) COMBI-MB: a phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM). J Clin Oncol 35(15_suppl):9506–9506.  https://doi.org/10.1200/JCO.2017.35.15_suppl.9506CrossRefGoogle Scholar
  7. Di Giacomo AM, Ascierto PA, Queirolo P et al (2015) Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol 26(4):798–803.  https://doi.org/10.1093/annonc/mdu577. Epub 2014 Dec 23CrossRefPubMedGoogle Scholar
  8. Fischer F, Haenel M, Moehle R et al (2011) Systemic and intrathecal chemotherapy followed by high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: a potentially curative approach? J Clin Oncol 29(Suppl):8005CrossRefGoogle Scholar
  9. Fischer L, Martus P, Weller M et al (2008) Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology 71:1102–1108CrossRefGoogle Scholar
  10. Fuentes R, Bonfill X, Exposito J (2006) Surgery versus radiosurgery for patients with a solitary brain metastasis from non-small cell lung cancer. Cochrane Database Syst Rev 1:CD004840Google Scholar
  11. Garell PC, Hitchon PW, Wen BC et al (1999) Stereotactic radiosurgery versus microsurgical resection for the initial treatment of metastatic cancer to the brain. J Radiosurg 2:1–5CrossRefGoogle Scholar
  12. Gaspar L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751CrossRefGoogle Scholar
  13. Hussain A, Brown PD, Stafford SL et al (2007) Stereotactic radiosurgery for brainstem metastases: survival, tumor control, and patient outcomes. Int J Radiat Oncol Biol Phys 67:521–524CrossRefGoogle Scholar
  14. Kocher M, Soffietti R, Abacioglu U, for the EORTC Radiation Oncology and Brain Tumor Groups et al (2011) Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of 1–3 cerebral metastases. results of the EORTC 22952-26001 study. J Clin Oncol 29:134–141Google Scholar
  15. Korfel A, Elter T, Thiel E et al (2013) Phase II study of CNS-directed chemotherapy uncluding high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 98:364–370CrossRefGoogle Scholar
  16. Linskey ME, Andrews DW, Asher AL et al (2010) The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol 96:45–68CrossRefGoogle Scholar
  17. Long GV, Atkinson V, Menzies AM, Lo S, Guminski AD, Brown MP, Gonzalez MM, Diamante K, Sandhu SK, Scolyer RA, Emmett L, McArthur GA (2017) A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the Anti-PD1 Brain Collaboration (ABC). J Clin Oncol 35(15_suppl):9508–9508.  https://doi.org/10.1200/JCO.2017.35.15_suppl.9508CrossRefGoogle Scholar
  18. Mahajan A, Ahmed S, MF MA, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, IE MC, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G (2017) Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1040–1048.  https://doi.org/10.1016/S1470-2045(17)30414-X. Epub 2017 Jul 4CrossRefPubMedPubMedCentralGoogle Scholar
  19. Mavrakis AN, Halpern EF, Barker FG 2nd et al (2005) Diagnostic evaluation of patients with a brain mass as the presenting manifestation of cancer. Neurology 65:908–911CrossRefGoogle Scholar
  20. Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500CrossRefGoogle Scholar
  21. Patchell RA, Tibbs PA, Regine WF et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485–1489CrossRefGoogle Scholar
  22. Patil CG, Pricola K, Garg SK et al (2012) Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev (9):CD006121Google Scholar
  23. Schackert G, Lindner C, Petschke S et al (2013) Retrospective study of 127 surgically treated patients with multiple brain metastases: indication, prognostic factors, and outcome. Acta Neurochir 155:379–387CrossRefGoogle Scholar
  24. Schoggl A, Kitz K, Reddy M et al (2000) Defining the role of stereotactic radiosurgery versus microsurgery in the treatment of single brain metastases. Acta Neurochir 142:621–626CrossRefGoogle Scholar
  25. Sloot S et al (2018) Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Cancer 124:297–305CrossRefGoogle Scholar
  26. Sperduto PW, Berkey B, Gaspar LE et al (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510–514CrossRefGoogle Scholar
  27. Sperduto PW, Chao ST, Sneed PK et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multiinstitutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77:655–661CrossRefGoogle Scholar
  28. Sperduto PW, Kased N, Roberge D et al. (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 30(4):419–25.  https://doi.org/10.1200/JCO.2011.38.0527. Epub 2011 Dec 27.CrossRefPubMedGoogle Scholar
  29. Suh JH (2010) Stereotactic radiosurgery for the management of brain metastases. N Engl J Med 362:1119–1127CrossRefGoogle Scholar
  30. Valiente M, Ahluwalia MS, Boire A, Brastianos PK, Goldberg SB, Lee EQ, Le Rhun E, Preusser M, Winkler F, Soffietti R (2018) The evolving landscape of brain metastasis. Trends Cancer 4(3):176–196.  https://doi.org/10.1016/j.trecan.2018.01.003. Epub 2018 Feb 21. ReviewCrossRefPubMedPubMedCentralGoogle Scholar
  31. Vecht CJ, Haaxma-Reiche H, Noordijk EM et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33:583–590CrossRefGoogle Scholar
  32. Weller M (Hrsg) (2008a) Für die Neuro-Onkologische Arbeitsgemeinschaft (NOA) in der Deutschen Krebsgesellschaft. Leitlinie Diagnostik und Therapie der zerebralen Metastasen. Zuckschwerdt, MünchenGoogle Scholar
  33. Weller M (Hrsg) (2008b) Für die Neuro-Onkologische Arbeitsgemeinschaft (NOA) in der Deutschen Krebsgesellschaft. Leitlinie Diagnostik und Therapie der Spinalen Metastasen und der Meningeosis neoplastica. Zuckschwerdt, MünchenGoogle Scholar
  34. Yamamoto M, Serizawa T, Shuto T et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15(4):387–395.  https://doi.org/10.1016/S1470-2045(14)70061-0. Epub 2014 Mar 10CrossRefPubMedGoogle Scholar
  35. Yen CP, Sheehan J, Patterson G et al (2006) Gamma knife surgery for metastatic brain stem tumors. J Neurosurg 105:213–219CrossRefGoogle Scholar

Weiterführende Literatur

  1. Diener HC, Putzki N, für die DGN et al (Hrsg) (2008) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme, StuttgartGoogle Scholar
  2. Louis DN, Ohgaki H, Wiestler OD et al (2007) World Health Organization classification of tumours. Pathology and genetics of tumours of the nervous system. The International Agency for Research on Cancer (IARC), 4th Aufl. IARC Press, LyonGoogle Scholar
  3. Schlegel U, Weller M, Westphal M (Hrsg) (2009) Neuroonkologische Therapie. Kohlhammer, StuttgartGoogle Scholar
  4. Tonn J-C, Westphal M, Rutka JT et al (Hrsg) (2010) Oncology of CNS tumors. Springer, Berlin/Heidelberg/New York/TokyoGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2020

Authors and Affiliations

  1. 1.Abteilung Klinische Neuroonkologie, Klinik und Poliklinik für NeurologieUniversitätsklinikum EssenEssenDeutschland
  2. 2.DKFZ Abteilung Translationale Neuroonkologie am Westdeutschen TumorzentrumDKTK Partnerstandort Universitätsklinikum EssenEssenDeutschland

Personalised recommendations